Clinical Trials Logo
  1. Home
  2. Squamous Cell Cancer
  3. NCT01384708
  4. Details
NCT01384708 Clinical Trial

Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

Squamous Cell Cancer Clinical Trial

Official title:
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01384708
Other study ID # GCO# 10-0982
Secondary ID
Status Completed
Phase Phase 0
First received June 28, 2011
Last updated January 7, 2016
Start date August 2010
Est. completion date October 2013

Study information
Verified date March 2014
Source Anandasabapathy, Sharmila, M.D.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The overall objective of this study is to determine whether high-resolution imaging of the esophagus during routine diagnostic upper endoscopy can assist clinicians in detecting and discriminating dysplastic (precancerous) areas. This high-resolution microendoscope (HRME) was developed by our collaborators at Rice University and provides > 1000x magnified images of the esophageal mucosa. The purpose of this study is to determine whether this device can be used to enhance the diagnostic accuracy of routine endoscopic screening for squamous cell cancer of the esophagus.

Recruitment information / eligibility
Status Completed
Enrollment 70
Est. completion date October 2013
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- known or suspected squamous cell neoplasia

- 18 years or older

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

Intervention

Drug:
• proflavine
1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)

Locations
Country Name City State
United States Mount Sinai Medical Center New York New York

Sponsors (2)
Lead Sponsor Collaborator
Anandasabapathy, Sharmila, M.D. William Marsh Rice University

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary to determine whether or not tissue is neoplastic or non-neoplastic 1 day No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06398418 - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors Phase 1
Completed NCT01358097 - Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy N/A
Completed NCT00705016 - Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 1/Phase 2
Active, not recruiting NCT04116320 - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Phase 1
Completed NCT01721525 - Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) Phase 1
Completed NCT01016769 - Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Phase 1/Phase 2
Completed NCT00661427 - Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Phase 2
Completed NCT00382031 - Zalutumumab in Patients With Non-curable Head and Neck Cancer Phase 3
Recruiting NCT04391049 - Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Phase 1
Recruiting NCT05932511 - Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer Early Phase 1
Completed NCT00815295 - Study of Sorafenib/Cetuximab in Head and Neck Cancer Phase 1/Phase 2
Completed NCT00542308 - Zalutumumab in Non-curable Patients With SCCHN Phase 2
Completed NCT00485485 - Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer Phase 2
Terminated NCT02376699 - Safety Study of SEA-CD40 in Cancer Patients Phase 1
Completed NCT00255476 - The IRESSA Novel Head and Neck Chemotherapy Evaluation Study Phase 2
Recruiting NCT03935893 - Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Phase 2
Terminated NCT00401401 - Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer Phase 1/Phase 2
Terminated NCT00559351 - RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03509467 - Using MC1R Genotype to Impact Melanoma Risk Behavior N/A